Genome (XKRX:314130) Change In Inventory : ₩-1,898 Mil (TTM As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Genome Change In Inventory?

Genome's change in inventory for the quarter that ended in Mar. 2025 was ₩0 Mil. It means Genome's inventory stayed the same from Dec. 2024 to Mar. 2025 .

Genome's change in inventory for the fiscal year that ended in Dec. 2024 was ₩-1,898 Mil. It means Genome's inventory increased by ₩1,898 Mil from Dec. 2023 to Dec. 2024 .

Genome's Total Inventories for the quarter that ended in Mar. 2025 was ₩0 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Genome's Days Inventory for the quarter that ended in Mar. 2025 was 105.22.

Inventory Turnover measures how fast the company turns over its inventory within a year. Genome's Inventory Turnover for the quarter that ended in Mar. 2025 was 0.87.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Genome's Inventory-to-Revenue for the quarter that ended in Mar. 2025 was 0.45.

Genome Change In Inventory Historical Data

The historical data trend for Genome's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genome Change In Inventory Chart

Genome Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Inventory

Get a 7-Day Free Trial

-154.36

-886.40

-1,694.18

-1,897.66

Genome Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Inventory	Get a 7-Day Free Trial															-537.35	-749.50	-700.79	89.98	-

Genome Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-1,898 Mil.

Genome (XKRX:314130) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Genome's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	2885.562	/	2502.353	*	365 / 4
	=	105.22

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Genome's Inventory Turnover for the quarter that ended in Mar. 2025 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	2502.353	/	2885.562
	=	0.87

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Genome's Inventory to Revenue for the quarter that ended in Mar. 2025 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	2885.562	/	6353.685
	=	0.45

Genome Change In Inventory Related Terms

Thank you for viewing the detailed overview of Genome's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Genome Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genome & Co (XKRX:314130) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

Innovalley A-801, Pangyo-ro 253, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13486

Website

http://www.genomecom.co.kr

Genome & Co is a Korean company engaged in researching and developing dietary supplements, cosmeceuticals, and new drugs. Its products pipeline includes immunooncology therapeutic supplement for treatment of immuno-oncology, lung cancer, colorectal cancer, stomach cancer, breast cancer, pancreatic cancer; dietary supplements for treating obesity and diabetes; cosmetics used for acne and atopic dermatitis; and also produces In Virto fertilization medicine.

Genome Headlines

No Headlines